Lymoribe Capsule contains Lymecycline 408 mg, a broad-spectrum tetracycline antibiotic effective against a variety of bacterial infections. Lymecycline acts by inhibiting bacterial protein synthesis, thereby preventing bacterial growth and replication. It is commonly prescribed for the treatment of acne vulgaris, respiratory tract infections, urinary tract infections, and certain types of skin infections caused by susceptible strains of bacteria. The capsule formulation ensures convenient oral administration and optimal bioavailability. Lymecycline demonstrates activity against both gram-positive and gram-negative organisms, including Propionibacterium acnes, Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli. It is generally well tolerated, with adverse effects such as gastrointestinal disturbances, photosensitivity, and hypersensitivity reactions being relatively uncommon. Lymoribe Capsule should be used with caution in patients with a history of hypersensitivity to tetracyclines, hepatic or renal impairment, and during pregnancy or lactation. It is important to complete the full prescribed course to prevent the development of bacterial resistance. Concomitant use with antacids, iron supplements, or dairy products may reduce absorption and should be avoided or spaced appropriately. Lymoribe Capsule provides an effective therapeutic option for managing bacterial infections when administered under medical supervision.